Drugs / AZD6280
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00824057 | Jan → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00750802 | Sep → Dec 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00681317 | Mar → Jul 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00681746 | Feb → Sep 2008 | anxiety | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00681317 ↗ |
| Action | Activate | “GABA receptor alpha-3 subunit positive allosteric modulator” CHEMBL1783256 ↗1“GABA receptor alpha-2 subunit positive allosteric modulator” CHEMBL1783256 ↗ |
| Modality | Small molecule | — CHEMBL1783256 ↗ |
| Route | Oral | “oral” NCT00681317 ↗ |
| Target | GABRA2 | “GABA receptor alpha-2 subunit positive allosteric modulator” CHEMBL1783256 ↗ |
| Target | GABRA3 | “GABA receptor alpha-3 subunit positive allosteric modulator” CHEMBL1783256 ↗ |